424 related articles for article (PubMed ID: 11744442)
1. Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium.
Partin AW; Mangold LA; Lamm DM; Walsh PC; Epstein JI; Pearson JD
Urology; 2001 Dec; 58(6):843-8. PubMed ID: 11744442
[TBL] [Abstract][Full Text] [Related]
2. Updated nomogram to predict pathologic stage of prostate cancer given prostate-specific antigen level, clinical stage, and biopsy Gleason score (Partin tables) based on cases from 2000 to 2005.
Makarov DV; Trock BJ; Humphreys EB; Mangold LA; Walsh PC; Epstein JI; Partin AW
Urology; 2007 Jun; 69(6):1095-101. PubMed ID: 17572194
[TBL] [Abstract][Full Text] [Related]
3. Prediction of pathological stage based on clinical stage, serum prostate-specific antigen, and biopsy Gleason score: Partin Tables in the contemporary era.
Tosoian JJ; Chappidi M; Feng Z; Humphreys EB; Han M; Pavlovich CP; Epstein JI; Partin AW; Trock BJ
BJU Int; 2017 May; 119(5):676-683. PubMed ID: 27367645
[TBL] [Abstract][Full Text] [Related]
4. An updated prostate cancer staging nomogram (Partin tables) based on cases from 2006 to 2011.
Eifler JB; Feng Z; Lin BM; Partin MT; Humphreys EB; Han M; Epstein JI; Walsh PC; Trock BJ; Partin AW
BJU Int; 2013 Jan; 111(1):22-9. PubMed ID: 22834909
[TBL] [Abstract][Full Text] [Related]
5. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update.
Partin AW; Kattan MW; Subong EN; Walsh PC; Wojno KJ; Oesterling JE; Scardino PT; Pearson JD
JAMA; 1997 May; 277(18):1445-51. PubMed ID: 9145716
[TBL] [Abstract][Full Text] [Related]
6. Prediction of patient-specific risk and percentile cohort risk of pathological stage outcome using continuous prostate-specific antigen measurement, clinical stage and biopsy Gleason score.
Huang Y; Isharwal S; Haese A; Chun FK; Makarov DV; Feng Z; Han M; Humphreys E; Epstein JI; Partin AW; Veltri RW
BJU Int; 2011 May; 107(10):1562-9. PubMed ID: 20875091
[TBL] [Abstract][Full Text] [Related]
7. Complexed prostate-specific antigen as a staging tool for prostate cancer: a prospective study in 420 men.
Sokoll LJ; Mangold LA; Partin AW; Epstein JI; Bruzek DJ; Dunn W; Mohr P; Wallerson G; Chan DW
Urology; 2002 Oct; 60(4 Suppl 1):18-23. PubMed ID: 12384158
[TBL] [Abstract][Full Text] [Related]
8. Improved clinical staging system combining biopsy laterality and TNM stage for men with T1c and T2 prostate cancer: results from the SEARCH database.
Freedland SJ; Presti JC; Terris MK; Kane CJ; Aronson WJ; Dorey F; Amling CL;
J Urol; 2003 Jun; 169(6):2129-35. PubMed ID: 12771734
[TBL] [Abstract][Full Text] [Related]
9. Probability of biochemical recurrence by analysis of pathologic stage, Gleason score, and margin status for localized prostate cancer.
Khan MA; Partin AW; Mangold LA; Epstein JI; Walsh PC
Urology; 2003 Nov; 62(5):866-71. PubMed ID: 14624910
[TBL] [Abstract][Full Text] [Related]
10. Are prostate carcinoma clinical stages T1c and T2 similar?
Billis A; Magna LA; Watanabe IC; Costa MV; Telles GH; Ferreira U
Int Braz J Urol; 2006; 32(2):165-71. PubMed ID: 16650293
[TBL] [Abstract][Full Text] [Related]
11. The impact of the biopsy Gleason score on PSA outcome for prostate cancer patients with PSA < or = 10 ng/ml and T1c,2a: implications for patient selection for prostate-only therapy.
D'Amico AV; Renshaw AA; Schultz D; Rocha S; Richie JP
Int J Radiat Oncol Biol Phys; 1999 Nov; 45(4):847-51. PubMed ID: 10571188
[TBL] [Abstract][Full Text] [Related]
12. The role of transrectal ultrasound-guided biopsy-based staging, preoperative serum prostate-specific antigen, and biopsy Gleason score in prediction of final pathologic diagnosis in prostate cancer.
Narayan P; Gajendran V; Taylor SP; Tewari A; Presti JC; Leidich R; Lo R; Palmer K; Shinohara K; Spaulding JT
Urology; 1995 Aug; 46(2):205-12. PubMed ID: 7542823
[TBL] [Abstract][Full Text] [Related]
13. [The 1992 TNM classification of T2 prostate cancer predicts pathologic stage and prognosis better than the revised 1997 classification].
Koh H; Maru N; Muramoto M; Wheeler TM; Scardino PT; Ohori M
Nihon Hinyokika Gakkai Zasshi; 2002 Jul; 93(5):595-601. PubMed ID: 12174634
[TBL] [Abstract][Full Text] [Related]
14. Validation of Partin tables and development of a preoperative nomogram for Japanese patients with clinically localized prostate cancer using 2005 International Society of Urological Pathology consensus on Gleason grading: data from the Clinicopathological Research Group for Localized Prostate Cancer.
Naito S; Kuroiwa K; Kinukawa N; Goto K; Koga H; Ogawa O; Murai M; Shiraishi T;
J Urol; 2008 Sep; 180(3):904-9; discussion 909-10. PubMed ID: 18635221
[TBL] [Abstract][Full Text] [Related]
15. Optimizing patient selection for dose escalation techniques using the prostate-specific antigen level, biopsy gleason score, and clinical T-stage.
D'Amico AV; Whittington R; Malkowicz SB; Schultz D; Renshaw AA; Tomaszewski JE; Richie JP; Wein A
Int J Radiat Oncol Biol Phys; 1999 Dec; 45(5):1227-33. PubMed ID: 10613317
[TBL] [Abstract][Full Text] [Related]
16. Substratification of stage T1C prostate cancer based on the probability of biochemical recurrence.
Gretzer MB; Epstein JI; Pound CR; Walsh PC; Partin AW
Urology; 2002 Dec; 60(6):1034-9. PubMed ID: 12475665
[TBL] [Abstract][Full Text] [Related]
17. Prediction of pathological stage in patients with clinical stage T1c prostate cancer: the new challenge.
Veltri RW; Miller MC; Mangold LA; O'Dowd GJ; Epstein JI; Partin AW
J Urol; 2002 Jul; 168(1):100-4. PubMed ID: 12050500
[TBL] [Abstract][Full Text] [Related]
18. Nomograms for the prediction of pathologic stage of clinically localized prostate cancer in Korean men.
Song C; Kang T; Ro JY; Lee MS; Kim CS; Ahn H
J Korean Med Sci; 2005 Apr; 20(2):262-6. PubMed ID: 15831998
[TBL] [Abstract][Full Text] [Related]
19. Relationship between percent positive biopsies and biochemical outcome after permanent interstitial brachytherapy for clinically organ-confined carcinoma of the prostate gland.
Merrick GS; Butler WM; Galbreath RW; Lief JH; Adamovich E
Int J Radiat Oncol Biol Phys; 2002 Mar; 52(3):664-73. PubMed ID: 11849788
[TBL] [Abstract][Full Text] [Related]
20. Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer.
Han M; Partin AW; Zahurak M; Piantadosi S; Epstein JI; Walsh PC
J Urol; 2003 Feb; 169(2):517-23. PubMed ID: 12544300
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]